文献速递炎症性肠病

克罗恩病或溃疡性结肠炎患者对维多珠单抗应答丧失及剂量强化恢复应答能力的系统评价与Meta分析

Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis.
PubMed 文献 · Clin Gastroenterol Hepatol · 2018-06-20

该系统评价与Meta分析检索截至2017年12月的文献,纳入10个队列,评估成人克罗恩病或溃疡性结肠炎患者对维多珠单抗维持治疗应答丧失的发生率及剂量强化恢复应答的能力。结果显示克罗恩病应答丧失发生率为47.9/100人年,溃疡性结肠炎为39.8/100人年,剂量强化使53.8%的继发性无应答者恢复应答。作者认为需进一步研究以指导临床决策。

要点

  • 克罗恩病患者对维多珠单抗维持治疗应答丧失的合并发生率为47.9/100人年(95%CI 26.3‒87.0;I²=74%)。
  • 溃疡性结肠炎患者应答丧失的合并发生率为39.8/100人年(95%CI 35.0‒45.3;I²=0%)。
  • 剂量强化使53.8%的继发性无应答者恢复应答(95%CI 21.8%‒82.9%;I²=77%)。

核心结论

  • 克罗恩病或溃疡性结肠炎患者中对维多珠单抗维持治疗应答丧失的比例较高,剂量强化可使超过半数的继发性无应答者恢复应答,需进一步研究以指导临床决策。

研究设计与样本

  • 系统评价与Meta分析,检索PubMed、Scopus及会议摘要(消化疾病周、欧洲克罗恩病和结肠炎组织、欧洲联合胃肠病学周)截至2017年12月,纳入10个实验性或观察性队列研究,对象为接受维多珠单抗治疗的成人克罗恩病或溃疡性结肠炎患者,多数患者既往接受过肿瘤坏死因子拮抗剂治疗。

主要发现

  • 克罗恩病患者应答丧失的合并发生率为47.9/100人年(95%CI 26.3‒87.0;I²=74%)。
  • 溃疡性结肠炎患者应答丧失的合并发生率为39.8/100人年(95%CI 35.0‒45.3;I²=0%)。
  • 剂量强化使53.8%的继发性无应答者恢复应答(95%CI 21.8%‒82.9%;I²=77%)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性,但作者在结论中提出需进一步研究以指导临床决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: Vedolizumab is effective and safe for the treatment of Crohn's disease (CD) and ulcerative colitis (UC). Little is known about the incidence rate of loss of response to vedolizumab maintenance therapy or whether dose intensification restores response to this drug. METHODS: We searched PubMed, Scopus and conference abstracts (Digestive Disease Week, European Crohn's and Colitis Organization, and United European Gastroenterology Week), through December 2017, for experimental or observational cohort studies of vedolizumab use in adult patients with CD or UC; we identified studies that provided sufficient data to determine the incidence rate of loss of response among initial responders and the ability of dose intensification to restore response. Two reviewers independently abstracted study data and outcomes and rated each study's risk of bias. The studies were evaluated for heterogeneity and publication bias. Summary estimates were calculated using random effects models. RESULTS: We analyzed data from 10 eligible cohorts; most patients had received prior treatment with a tumor necrosis factor antagonist. The pooled incidence rates of loss of response were 47.9 per 100 person-years of follow up (95% CI, 26.3‒87.0; I2 = 74%) among patients with CD and 39.8 per 100 person-years of follow up (95% CI, 35.0‒45.3; I2 = 0%) among patients with UC. Dose intensification restored response to the drug in 53.8% of secondary non-responders (95% CI, 21.8%‒82.9%; I2 = 77%). CONCLUSIONS: In a systematic review and meta-analysis, we found high proportions of patients with CD or UC to lose responsiveness to vedolizumab maintenance therapy. Dose intensification restores responsiveness to more than half of these patients. Additional studies are warranted to inform clinical decision making.

来源:Clin Gastroenterol Hepatol,查看原文。版权归原作者所有。

引用

  1. Peyrin-Biroulet L, Danese S, Argollo M, et al. Loss of Response to Vedolizumab and Ability of Dose Intensification to Restore Response in Patients With Crohn's Disease or Ulcerative Colitis: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol. 2018. PMID: 29935327. doi:10.1016/j.cgh.2018.06.026

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。